Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ninety eight patients with cervical cancer were subjected to endolymphatic chemotherapy with multiple cytostatic drugs to affect metastatic lymph nodes. A comcentrated mixture of chemotherapeutic drugs (total amount about 20 ml) was injected into plantar lymph vessels, an interval being 10-14 days. The combinations and dosage of the drugs were as follows: thio-TEPA (100-150 mg) or cyclophosphamid (1000-2000 mg)+methotrexate (100 mg)+5-fluorouracil (1000-1500 mg). Subsequently, 76 patients underwent an extended extirpation of the uterus with adnexa, and their lymph-nodes were studied morphologically. It was found that the number of metastases into the lymphnodes was considerably less than it had been expected. Of 45 patients with the disease stage II metastases have been found only in 3 cases (7%). Of 24 patients with cancer stage III the lymphnodes were involved in 4 cases (16.6%). According to the literature data metastatic involvement of the lymphnodes is on an average encountered in 36% for stage II and in 51% - for stage III.
 ...
PMID:[Metastasis to the lymph nodes as an index of the effectiveness of preoperative endolymphatic polychemotherapy of cervix cancer]. 34 11

Data are presented on 3359 breast cancer patients treated at the Petrov Research Institute of Oncology of the USSR Ministry of Health. For the 20-year period (from 1955 to 1975) not large but statistically significant increase of the 5-year survival was noted which achieved 64.7% in 1971-1975. The rise of survival was observed in patients aged under 50, subjected to adjuvant chemotherapy (Thio-TEPA, 5-Ftoruracil). Development of distant metastases was the cause of death of breast cancer patients within the 15 years after the beginning of treatment in 68.8% of cases. Only 7.6% of patients expired from distant metastases in 15-20 years following operation.
 ...
PMID:End results of treatment of breast cancer patients. 400 Mar 14

Out of 3718 breast cancer patients treated at Petrov Research Institute of Oncology 262 patients [7%] proved to have minimal (less than 1 cm in diameter) form of breast cancer. Treatment of minimal breast cancer provides favorable end-results (5-year survival 91.2%, 10-year survival--79.5%). Nevertheless, minimal forms of breast cancer are also characterized by the ability to regional (in 28.5% of cases) and distant (in 10.3% of cases) metastatic spread. Organ preserving operations (sectoral resection of one block with axillary-subclavicular fat) are often (18.5%) followed by local-regional recurrences of the disease. Application of adjuvant chemotherapy with Thio-TEPA in patients with minimal breast cancer with regional metastases decreases frequency of recurrences and distant metastases by 17.8%.
 ...
PMID:Minimal breast cancer. Clinical characteristics and treatment results. 630 93

Twenty-two patients with metastatic breast cancer were treated by a combination of testosterone and N,N',N'', triethylenethiophosphoramide (Thio-TEPA). All had undergone mastectomy and received radiation; six had had an oophorectomy and 12 had had oophorectomy and adrenalectomy. For its marrow-stimulating effect testosterone was given intramuscularly, 100 mg. daily for five days; then 100 mg. of depo-testosterone was given intramuscularly once a week. On the sixth day of treatment, 15 mg. of Thio-TEPA was given intramuscularly and repeated daily or every second day until a definite depression of the leukocyte and/or platelet counts occurred. To 15 patients a total dose of 200 mg. or more of triethylenethiophosphoramide was given. Thirteen patients improved subjectively and five of these improved objectively. The duration of improvement varied between one and 12 months. Treatment was most effective in patients with bony metastases.
 ...
PMID:The use of triethylenethiophosphoramide (Thio-TEPA) in the treatment of metastatic carcinoma of the breast. 1392 82

A Phase II study of combined modality therapy of leptomeningeal metastases (LM) in melanoma was carried out. Central nervous system (CNS) metastases occur commonly in patients with clinically advanced melanoma. 16 patients (median age 47; range 32-62 years) with LM due to metastatic melanoma were treated. Neurologic presentation included: headache (9 patients); cranial neuropathies (6); cauda equina syndrome (4); gait ataxia (3); hemiparesis (2); radiculopathy (2); myelopathy (1); and seizure (1). All patients underwent CNS staging followed by radiotherapy (14 patients) and intraventricular chemotherapy (methotrexate 16 patients; ara-C 13 patients; thio-TEPA 7 patients). CNS imaging demonstrated: interrupted CSF flow (9 patients); parenchymal brain metastases (7); spinal cord subarachnoid nodules (5); hydrocephalus (3); and epidural spinal cord compression (2). CSF cytologic responses were seen in 4 patients to first-, 6 to second-, and 3 to third-line chemotherapy. Treatment-related toxicity included 13 patients with meningitis (12 chemical; 1 bacterial) and 12 patients (18 episodes) with myelosupression (4 episodes secondary to intraventricular chemotherapy). Median survival was 4 months (range: 2-8). Twelve patients (75%) died of progressive LM or combined LM and systemic disease progression. LM in patients with metastatic melanoma may be palliated with combined modality therapy, however, median survival is quite short suggesting a re-evaluation of such an approach in similarly affected patients.
 ...
PMID:Leptomeningeal metastases due to melanoma. 2154 42